Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64264681 + JNJ-67856633 combination study in B-cell NHL and CLL
NL-OMON52350Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-64264681 and JNJ-67856633 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Recommended Phase 2 dose determination and Safety at RP2D. Started Mar 2022; status: active, not recruiting.
02
Drugs
JNJ-64264681JNJ-67856633
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON52350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52350.